131 results on '"Vojdanian, Mahdi"'
Search Results
2. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
3. Upregulation of Unfolded Protein Response and ER Stress–Related IL-23 Production in M1 Macrophages from Ankylosing Spondylitis Patients
4. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
5. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
6. Monocyte-derived and M1 macrophages from ankylosing spondylitis patients released higher TNF-α and expressed more IL1B in response to BzATP than macrophages from healthy subjects
7. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
8. Identification of RELN variant p.(Ser2486Gly) in an Iranian family with ankylosing spondylitis; the first association of RELN and AS
9. The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial
10. Ankylosing spondylitis monocyte-derived macrophages express increased level of A2A adenosine receptor and decreased level of ectonucleoside triphosphate diphosphohydrolase-1 (CD39), A1 and A2B adenosine receptors
11. A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-d-mannuronic acid in rheumatoid arthritis patients
12. The effects of β-d-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line
13. Association of Killer Cell Immunoglobulin-like Receptor (KIR) Genes and their HLA Ligands with Susceptibility to Takayasu Arteritis in the Iranian Population
14. Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis
15. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
16. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial
17. A2A adenosine receptor agonist reduced MMP8 expression in healthy M2-like macrophages but not in macrophages from ankylosing spondylitis patients
18. Additional file 1 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
19. Additional file 3 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
20. Additional file 2 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
21. Additional file 4 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
22. Validity and reliability of the Persian version of Behçet’s disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation
23. Prototypic P2X7 Receptor Agonist, BzATP, Induced the Expression of Unfolded Protein Response Genes in Human M1 Macrophages
24. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
25. Authors and affiliations.
26. The New Perceptions on Life of Iranian Patients with Ankylosing Spondylitis: A Qualitative Study
27. Upmodulation of Unfolded Protein Response and ER Stress-Related IL-23 Production in M1 Macrophages From Ankylosing Spondylitis Patients
28. Activation of adenosine A2A receptor induced interleukin-23 mRNA expression in macrophages of ankylosing spondylitis patients
29. P2 receptors mRNA expression profiles in macrophages from ankylosing spondylitis patients and healthy individuals
30. Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis
31. microRNA involvement in the regulation of survivin in peripheral blood mononuclear cells from rheumatoid arthritis patients
32. Association study of copy number variation in BMP8A gene with the risk of ankylosing spondylitis in Iranian population
33. Increased inflammatory responsiveness of peripheral blood mononuclear cells (PBMCs) to in vitro NOD2 ligand stimulation in patients with ankylosing spondylitis
34. Rare Mediterranean Fever (MEFV) Gene Polymorphisms Are Associated with Ankylosing Spondylitis in Turkish and Iranian Population
35. P2 receptors mRNA expression profiles in macrophages from ankylosing spondylitis patients and healthy individuals.
36. The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report
37. Determination of ETS1 gene single nucleotide polymorphism in Iranian patients with ankylosing spondylitis
38. The effects of β-d-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line
39. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
40. Upregulation of transforming growth factor-B1 gene in ankylosing spondylitis patients
41. Gene expression profile of proinflammatory cytokines in Iranian patients with ankylosing spondylitis
42. Ankylosing spondylitis M-CSF-derived macrophages are undergoing unfolded protein response (UPR) and express higher levels of interleukin-23
43. Identification of RELNvariant p.(Ser2486Gly) in an Iranian family with ankylosing spondylitis; the first association of RELNand AS
44. Association study of copy number variation in BMP8A gene with the risk of ankylosing spondylitis in Iranian population.
45. Gene Expression Profile of Proinflammatory Cytokines in Iranian Patients With Ankylosing Spondylitis
46. Ankylosing spondylitis monocyte-derived macrophages express increased level of A2A adenosine receptor and decreased level of ectonucleoside triphosphate diphosphohydrolase-1 (CD39), A1 and A2B adenosine receptors.
47. Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis.
48. Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property.
49. Ankylosing spondylitis M-CSF-derived macrophages are undergoing unfolded protein response (UPR) and express higher levels of interleukin-23.
50. Validity and reliability of the Persian version of Behçet’s disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.